A gas chromatography-mass spectrometry (GC-MS) metabolomic approach in human colorectal cancer (CRC): the emerging role of monosaccharides and amino acids.
Colorectal cancer (CRC)
D-mannose
amino acids
metabolomics
methionine
monosaccharides
Journal
Annals of translational medicine
ISSN: 2305-5839
Titre abrégé: Ann Transl Med
Pays: China
ID NLM: 101617978
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
entrez:
12
2
2020
pubmed:
12
2
2020
medline:
12
2
2020
Statut:
ppublish
Résumé
Colorectal cancer (CRC) has been confirmed to be the third most commonly diagnosed cancer in males and the second in females. We investigated the blood plasma metabolome in CRC patients and in healthy adults to elucidate the role of monosaccharides, amino acids, and their respective metabolic pathways as prognostic factors in patients with CRC. Fifteen patients with CRC and nine healthy adults were enrolled in the study and their blood plasma samples analyzed by gas chromatography-mass spectrometry (GC-MS). Univariate Student's Overall, 125 metabolites were identified in plasma samples by GC-MS. In CRC patient samples, nine metabolites, including D-mannose and fructose, were significantly more abundant than in controls; conversely, eleven amino derivatives were less abundant, including methionine, valine, lysine, and proline. Methionine was significantly less abundant in died patients compared with survivors. The most significantly altered metabolic pathways in CRC patients are those involving monosaccharides (primarily the catabolic pathway of fructose and D-mannose), and amino acids (primarily methionine, valine, leucine, and isoleucine). The abundance of D-mannose in CRC patient samples contributes to inhibiting the growth of cancer cells, while the abundance of fructose may be consistent either with low consumption of fructose by aerobic glycolysis within cancer cells or with a high bioavailability of fructose from diet. The reduction in methionine concentration may be related to increased activity of the threonine and methionine catabolic pathways, confirmed by high levels of α-hydroxybutyrate.
Sections du résumé
BACKGROUND
BACKGROUND
Colorectal cancer (CRC) has been confirmed to be the third most commonly diagnosed cancer in males and the second in females. We investigated the blood plasma metabolome in CRC patients and in healthy adults to elucidate the role of monosaccharides, amino acids, and their respective metabolic pathways as prognostic factors in patients with CRC.
METHODS
METHODS
Fifteen patients with CRC and nine healthy adults were enrolled in the study and their blood plasma samples analyzed by gas chromatography-mass spectrometry (GC-MS). Univariate Student's
RESULTS
RESULTS
Overall, 125 metabolites were identified in plasma samples by GC-MS. In CRC patient samples, nine metabolites, including D-mannose and fructose, were significantly more abundant than in controls; conversely, eleven amino derivatives were less abundant, including methionine, valine, lysine, and proline. Methionine was significantly less abundant in died patients compared with survivors. The most significantly altered metabolic pathways in CRC patients are those involving monosaccharides (primarily the catabolic pathway of fructose and D-mannose), and amino acids (primarily methionine, valine, leucine, and isoleucine).
CONCLUSIONS
CONCLUSIONS
The abundance of D-mannose in CRC patient samples contributes to inhibiting the growth of cancer cells, while the abundance of fructose may be consistent either with low consumption of fructose by aerobic glycolysis within cancer cells or with a high bioavailability of fructose from diet. The reduction in methionine concentration may be related to increased activity of the threonine and methionine catabolic pathways, confirmed by high levels of α-hydroxybutyrate.
Identifiants
pubmed: 32042743
doi: 10.21037/atm.2019.12.34
pii: atm-07-23-727
pmc: PMC6989984
doi:
Types de publication
Journal Article
Langues
eng
Pagination
727Informations de copyright
2019 Annals of Translational Medicine. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: The authors have no conflicts of interest to declare.
Références
World J Clin Cases. 2018 Dec 6;6(15):869-881
pubmed: 30568941
Cell Metab. 2016 Jan 12;23(1):27-47
pubmed: 26771115
Gen Physiol Biophys. 2017 Dec;36(5):513-520
pubmed: 29372684
Ann Oncol. 2014 Aug;25(8):1609-15
pubmed: 24827130
Mol Cancer. 2008 Sep 18;7:72
pubmed: 18799019
Mol Cell Proteomics. 2011 Jan;10(1):M110.002717
pubmed: 21097542
Biomed Chromatogr. 2017 Nov;31(11):
pubmed: 28475217
J Cancer. 2019 Jan 1;10(1):43-50
pubmed: 30662524
Metabolites. 2013 Jul 05;3(3):552-74
pubmed: 24958139
Clin Proteomics. 2018 Mar 2;15:9
pubmed: 29507546
Cancer Treat Rev. 2012 Oct;38(6):726-36
pubmed: 22342103
Oncotarget. 2017 Nov 11;8(62):105819-105831
pubmed: 29285295
Carcinogenesis. 2012 Feb;33(2):427-35
pubmed: 22159228
Br J Cancer. 2015 Jul 14;113(2):268-74
pubmed: 26035703
Methods Mol Biol. 2018;1765:229-240
pubmed: 29589312
Int J Cancer. 2019 Sep 1;145(5):1221-1231
pubmed: 30665271
J Proteome Res. 2013 Jun 7;12(6):3000-9
pubmed: 23675754
Br J Cancer. 2016 Sep 27;115(7):848-57
pubmed: 27560555
J Proteome Res. 2009 Jan;8(1):352-61
pubmed: 19063642
Dis Markers. 2018 Jun 19;2018:2959801
pubmed: 30018674
Nat Protoc. 2011 Jun 30;6(7):1060-83
pubmed: 21720319
Mol Cell Proteomics. 2010 Feb 10;:
pubmed: 20147338
Curr Nutr Rep. 2013 Mar;2(1):19-26
pubmed: 23396869
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
J Proteome Res. 2009 Oct;8(10):4844-50
pubmed: 19678709
Nucleic Acids Res. 2010 Jul;38(Web Server issue):W71-7
pubmed: 20457745
Malays J Med Sci. 2018 Sep;25(5):16-34
pubmed: 30914860
Int J Mol Sci. 2018 Oct 26;19(11):
pubmed: 30373199
Cancers (Basel). 2018 Jul 27;10(8):
pubmed: 30060469
Int J Cancer. 2019 Jul 1;145(1):221-231
pubmed: 30560999
Bioinformatics. 2005 Apr 15;21(8):1635-8
pubmed: 15613389
Cancer Res. 2009 Jun 1;69(11):4918-25
pubmed: 19458066
J Proteome Res. 2012 Apr 6;11(4):2282-300
pubmed: 22304416
Cancer. 2017 Oct 15;123(20):4066-4074
pubmed: 28640361
Cancer Metab. 2016 Jun 06;4:11
pubmed: 27275383
Nucleic Acids Res. 2018 Jul 2;46(W1):W486-W494
pubmed: 29762782
Proc Natl Acad Sci U S A. 2017 Sep 12;114(37):E7697-E7706
pubmed: 28847964
J Cell Biochem. 2019 Jun;120(6):10767-10776
pubmed: 30672027
FASEB J. 2005 May;19(7):780-2
pubmed: 15774576
PLoS One. 2018 Dec 21;13(12):e0208584
pubmed: 30576312
Cancer Lett. 2014 Feb 1;343(1):33-41
pubmed: 24041867
Metabolomics. 2012 Aug;8(4):643-653
pubmed: 22833708
Science. 1956 Aug 10;124(3215):269-70
pubmed: 13351639
J Mass Spectrom. 2013 Apr;48(4):487-96
pubmed: 23584942
Trends Biochem Sci. 2017 Apr;42(4):274-284
pubmed: 28196646
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Carcinogenesis. 2017 Feb 1;38(2):162-167
pubmed: 28062409
Nature. 2018 Nov;563(7733):719-723
pubmed: 30464341